Elevated plasma MB creatine phosphokinase activity. A specific marker for myocardial infarction in perioperative patients

1976 ◽  
Vol 136 (4) ◽  
pp. 421-424 ◽  
Author(s):  
R. Roberts
Keyword(s):  
Myocardial Infarction ◽  
Creatine Phosphokinase ◽  
Specific Marker ◽  
Elevated Plasma

Detection of coronary disease patients at high risk for recurrent myocardial infarction by elevated plasma inactive creatine kinase B protein levels

1981 ◽  
Vol 101 (5) ◽  
pp. 561-569 ◽  
Author(s):  
Michael H. Burnam ◽  
Marisa A. Crouch ◽  
Christopher Y.C. Chew ◽  
Winifred Carnegie ◽  
Harvey Hecht ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Creatine Kinase ◽  
High Risk ◽  
Coronary Disease ◽  
Elevated Plasma ◽  
Protein Levels ◽  
Recurrent Myocardial Infarction ◽  
Creatine Kinase B

Abstract 3532: Lipoprotein-Associated Phospholipase A 2 and High Sensitivity C-Reactive Protein Levels and the Prediction of Cardiovascular Risk Among Coronary Artery Disease Patients With Differing Clinical Presentations

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Heidi T May ◽  
Jeffrey L Anderson ◽  
Benjamin D Horne ◽  
Robert R Pearson ◽  
Robert L Wolfert ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Coronary Artery Disease ◽  
Acute Myocardial Infarction ◽  
Coronary Artery ◽  
High Sensitivity ◽  
Phospholipase A ◽  
Specific Marker ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Artery Disease

Background : Inflammation plays a role in the development and progression of coronary artery disease (CAD), with circulating markers of vascular inflammation being used in risk assessment including high sensitivity C-reactive protein (hsCRP) and lipoprotein-associated phospholipase A 2 (LpPLA 2 ). While hsCRP responds to the systemic inflammatory stimulus of acute myocardial infarction (AMI), LpPLA 2 has been proposed to be more vascular-specific and to vary minimally based upon clinical presentation. To test this hypothesis, we evaluated both biomarkers among CAD patients presenting with stable angina (SA), unstable angina (USA) or acute myocardial infarction (AMI). Methods : LpPLA 2 (PLAC TM test, diaDexus, Inc.) and hsCRP were measured from samples donated by consenting patients (N=1,010) enrolled in the registry of the Intermountain Heart Collaborative Study that underwent angiographic evaluation for CAD. Patients were categorized by presentation status (SA=637; USA=205; and AMI=168), stratified according to median levels of LpPLA 2 (350.2 ng/mL) and hsCRP above and below 3 mgl/L and followed for 7.5 ± 2.4 years for CAD death. Results : Age averaged 64 ± 12 years and 70% were male. While median hsCRP (mg/L) levels differed significantly by presentation [2.86, 2.80, and 13.7 for SA, USA, and AMI, respectively (p<0.0001)], median LpPLA 2 (ng/mL) levels [350.2, 353.1, and 348.1 for SA, USA, and AMI, respectively (p=0.67)], did not. LpPLA 2 was not only a better predictor of CAD death among the entire cohort (LpPLA 2 : adjusted Hazard Ratio [HR]= 1.47, p=0.04; hsCRP: adjusted HR=0.95, p=0.81), it was a better predictor among patients presenting with AMI (LpPLA 2 : adjusted HR3 1.80, p=0.30; hsCRP adjusted HR=0.76, p=0.63). Conclusions : Among CAD patients, LpPLA 2 varies minimally among differing presentations compared to hsCRP and is a better a predictor of CAD death among those presenting with AMI. This information supports the hypothesis that LpPLA 2 is a vascular specific marker of inflammation and independent of transient systemic inflammatory effects.

ASSESSMENT OF BIOCHEMICAL PARAMETERS IN DIABETIC AND NON-DIABETIC ACUTE MYOCARDIAL INFARCTION PATIENTS

2021 ◽  
Vol 5 (4) ◽  
Author(s):  
Darshna Jain
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Creatine Phosphokinase ◽  
Density Lipoprotein ◽  
Normal Blood ◽  
Cardiac Markers

Background: The present study was design to assess the level of altered lipid profile, lipoprotein sub fractions, oxidative stress and antioxidants in coronary artery disease with type-2 diabetes mellitus’s patients and non diabetic patients. Methods: This case–control study included 300 subjects; out of which, 100 subjects were with normal blood glucose level and with normal ECG (Normal, N), 100 subjects  were with normal blood glucose level and AMI (non-diabetic and AMI, N-AMI) and 100 subjects were with diabetes and AMI (Diabetic and AMI, D-AMI) Results: D-AMI individuals had high level of total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), and low level of high density lipoprotein (HDL) in comparison to N-AMI individuals. The cardiac markers such as Troponin I, creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and C-reactive protein (CRP) levels were significantly increased in patients suffering from myocardial infarction with diabetes mellitus (DM) compared to patients of myocardial infarction without DM. The antioxidant superoxide dismutase (SOD) and glutathione (GSH) were lower in D-AMI patients than in N-AMI. However, levels of malondialdehyde (MDA) and catalase (CAT) were higher in D-AMI than in N-AMI controls. Conclusion: Our study suggested that patients with D-AMI have elevated cardiac markers and reduced antioxidants levels as compared to N-AMI patient. Keywords: Diabetes Mellitus, Acute Myocardial Infarction, Creatine Phosphokinase, Glutathione

Creatine Phosphokinase Activity in Myocardial Infarction, Heart Failure, and Following Various Diagnostic and Therapeutic Procedures

1968 ◽  
Vol 14 (12) ◽  
pp. 1185-1196 ◽  
Author(s):  
Leonard V Crowley
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Electroconvulsive Therapy ◽  
Cardiac Failure ◽  
Creatine Phosphokinase ◽  
Coronary Arteriography ◽  
Surgical Operation ◽  
Patients With Heart Failure ◽  
Therapeutic Procedures ◽  
Infarction Heart

Abstract The creatine phosphokinase(CPK) test based on the method of Okinaka et al. (1) was compared with the glutamic oxalacetic transaminase (GOT) test of Reitman and Frankel (2) in patients with myocardial infarction, cardiac failure, and following various diagnostic and therapeutic procedures. The CPK method used was somewhat less discriminatory than the GOT method in detecting myocardial infarction. The CPK test possessed greater specificity, since it was not elevated in congestive cardiac failure, while the GOT test was elevated in 25% of the patients with heart failure. Therefore, the CPK test offered a real advantage when evaluating suspected infarction in the presence of cardiac failure. CPK activity may be elevated when the GOT test is normal, indicating the advantage of performing more than one enzyme procedure in suspected myocardial infarction. Both GOT and CPK were elevated in many patients following surgical operation and cardiac catheterization. No CPK elevations were encountered after electroconvulsive therapy, and CPK was only occasionally elevated following coronary arteriography.

A Study of the Problems of Inactivation of Creatine Kinase in Serum

1972 ◽  
Vol 18 (4) ◽  
pp. 330-334 ◽  
Author(s):  
Fram R Dalal ◽  
Jonathan Cilley ◽  
Seymour Winsten
Keyword(s):  
Myocardial Infarction ◽  
Creatine Kinase ◽  
Room Temperature ◽  
Creatine Phosphokinase ◽  
Serum Creatine Kinase ◽  
Sulfhydryl Groups ◽  
The Other ◽  
Clinical Pattern

Abstract Addition of sulfhydryl groups to the reaction mixture, to stabilize serum creatine kinase (creatine phosphokinase, CPK), results in apparent increases in the activity of this enzyme in many sera. In addition, in sera from patients just after myocardial infarction, assays for sulfhydryl-activated CPK have a different clinical pattern than do those for CPK assayed without sulfhydryl activators: activities are greater and remain abnormally high longer in assays in which the enzyme is sulfhydryl activated. If the assay is done without sulfhydryl activators present, technical difficulties appear, because CPK in serum is rapidly inactivated at room temperature. CPK is apparently inactivated in at least two ways. One, which is irreversible, is inhibited by albumin; the other, which is reversible by sulfhydryl groups, seems to result from the presence of substances in the pooled serum used that are both protein bound and free.

scholarly journals Serum Apoprotein (ApoA1 and ApoB) in Myocardial infarction

1970 ◽  
Vol 26 (2) ◽  
pp. 62-66
Author(s):  
Khadija Akther Jhuma ◽  
MM Hoque
Keyword(s):  
Myocardial Infarction ◽  
Lipid Profile ◽  
Case Control Study ◽  
Profile Measurement ◽  
Specific Marker ◽  
Matched Healthy Control ◽  
Key Word ◽  
Healthy Control ◽  
The Mean ◽  
Control Study

30 diagnosed cases (Male26, Female 4) of MI (myocardial infarction) with the mean age of 55.5±9.8 years (range 40- 70 years) were included in a case control study to evaluate their apoprotein status. Serum apoA1 and apoB were measured and compared with those of age and sex matched healthy control subjects. Mean serum apoA1 concentration found significantly low in MI cases (91.84± 11.2 mg/dl) compared to control ( 123.2±10.5 mg/dl) and that of apoB found significantly high in MI cases( 135.3± 23.0 mg/dl ) compared to control (66.2±10.0 mg/dl).Serum apoB/apoA1 ratio of MI cases (1.49±0.3) also found significantly higher than that of control (0.54±0.1) .Since the serum apoA1 and apoB concentration stand for relatively more comprehensive measure of antiatherogenic and atherogenic potential respectively rather than the traditional lipid profile ; measurement of this apoprotein and their ratio may be more robust and specific marker for identification of individuals at risk of MI even in individuals with normal traditional lipid profile. Key word: ApoA1, ApoB, MI DOI: 10.3329/jbcps.v26i2.4181 J Bangladesh Coll Phys Surg 2008; 26: 62-66

Sign in / Sign up

Export Citation Format

Share Document